OpGen, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPGN research report →
Companywww.opgen.com
OpGen, Inc. , a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
- CEO
- Christian-Laurent Benoit Bonte
- IPO
- 2015
- Employees
- 85
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $242.67M
- P/E
- 2.21
- P/S
- 1.69
- P/B
- 1.49
- EV/EBITDA
- 2.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.93%
- Op Margin
- 73.10%
- Net Margin
- 76.04%
- ROE
- 77.64%
- ROIC
- 52.46%
Growth & Income
- Revenue
- $5.20M · 52.02%
- Net Income
- $11.99M · 136.71%
- EPS
- $2.44 · 105.88%
- Op Income
- $324.72K
- FCF YoY
- 67.79%
Performance & Tape
- 52W High
- $34.00
- 52W Low
- $0.00
- 50D MA
- $22.24
- 200D MA
- $8.61
- Beta
- -1.93
- Avg Volume
- 5.58K
Get TickerSpark's AI analysis on OPGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our OPGN Coverage
We haven't published any research on OPGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OPGN Report →